Patents by Inventor Jasbir S. Seehra

Jasbir S. Seehra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190282663
    Abstract: The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, facture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 19, 2019
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY
  • Publication number: 20190284251
    Abstract: The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 19, 2019
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY
  • Patent number: 7252820
    Abstract: Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein may be administered alone, or in combination with a cytokine, lymphokine, or hematopoietic factor.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: August 7, 2007
    Assignee: Genetics Institute, LLC
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
  • Patent number: 6916841
    Abstract: Novel compounds are disclosed which inhibit the activity of phospholipase enzymes in a mammal, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: July 12, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Jasbir S. Seehra, Neelu Kaila, John C. McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang
  • Patent number: 6881404
    Abstract: Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: April 19, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
  • Patent number: 6828344
    Abstract: Novel compounds are disclosed which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: December 7, 2004
    Assignee: Genetics Institute, LLC
    Inventors: Jasbir S. Seehra, Neelu Kaila, John McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang
  • Patent number: 6801860
    Abstract: The present invention provides for crystalline cPLA2. The crystal structure of cPLA2 has also been solved using such material. Models based upon such crystal structure are also provided. Methods of identifying inhibitors of cPLA2 activity and membrane binding using such models are also disclosed.
    Type: Grant
    Filed: February 15, 1999
    Date of Patent: October 5, 2004
    Assignee: Genetics Institute, LLC
    Inventors: Andrea Dessen, William S. Somers, Mark L. Stahl, Jasbir S. Seehra
  • Patent number: 6630496
    Abstract: This invention provides substituted indole and indoline compounds useful in inhibiting phospholipase activity, particularly including cytosolic phospholipase A2 (cPLA2) activity, as well as pharmaceutical compositions containing the compounds and methods of using them to treat various maladies, including pain and inflammatory conditions.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: October 7, 2003
    Assignee: Genetics Institute LLC
    Inventors: Jasbir S. Seehra, Neelu Kaila, John C. McKew, Jean E. Bemis, YiBin Xiang, Lihren Chen
  • Publication number: 20030153751
    Abstract: Novel compounds are disclosed which inhibit the activity of phospholipase enzymes in a mammal, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
    Type: Application
    Filed: May 8, 2002
    Publication date: August 14, 2003
    Applicant: American Home Products Corporation
    Inventors: Jasbir S. Seehra, Neelu Kaila, John C. McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang
  • Publication number: 20030068300
    Abstract: Crystallographic and NMR solution structures of human IL-6 are reported. The invention provides models and systems incorporating such structures which are useful for identifying IL-6/IL-6 receptor interactions and for identification of agonists and antagonists of such interactions. Crystalline human IL-6 is also provided.
    Type: Application
    Filed: September 19, 2002
    Publication date: April 10, 2003
    Applicant: Wyeth
    Inventors: William S. Somers, Mark L. Stahl, Jasbir S. Seehra, Guang-Yi Xu, Thomas E. McDonagh, Hsiang-Ai Yu, Jin Hong
  • Patent number: 6500853
    Abstract: This invention concerns compounds and pharmaceutical compositions useful for treating or preventing inflammatory conditions in a mammal, the methods comprising administration of novel pharmaceutically useful compounds of the general formulae: or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined in the specification.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: December 31, 2002
    Assignee: Genetics Institute, LLC
    Inventors: Jasbir S. Seehra, John C. McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang, Lihren Chen, John L. Knopf
  • Patent number: 6461604
    Abstract: Crystallographic and NMR solution structures of human IL-6 are reported. The invention provides models and systems incorporating such structures which are useful for identifying IL-6/IL-6 receptor interactions and for identification of agonists and antagonists of such interactions. Crystalline human IL-6 is also provided.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: October 8, 2002
    Assignee: Genetics Institute, LLC
    Inventors: William S. Somers, Mark L. Stahl, Jasbir S. Seehra, Guang-Yi Xu, Thomas E. McDonagh, Hsiang-Ai Yu, Jin Hong
  • Publication number: 20020127691
    Abstract: Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.
    Type: Application
    Filed: November 27, 2001
    Publication date: September 12, 2002
    Applicant: Genetics Institute, Inc.
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
  • Patent number: 6413760
    Abstract: Highly purified mocarhagin, a cobra venom protease, is disclosed. Pharmaceutical compositions and therapeutic uses of the highly purified protease are also provided. Polynucleotides encoding such protease and related proteases are also disclosed.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: July 2, 2002
    Assignee: Genetics Institute, Inc.
    Inventors: Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
  • Patent number: 5430019
    Abstract: Methods of treating mammalian soft tissue injuries such as thermal and chemical burns, surgical incisions, ulcers, abrasions, skin grafts, and nervous tissue damage by administering a therapeutically effective amount of homogeneous K-fibroblast growth factor are provided. Also provided are methods of treating mammalian musculo-skeletal disorders such as bone grafts, bone fractures, ligament tears, cartilage tears, tendon tears, bursa inflammation and tendon inflammation by administering a therapeutically effective amount of homogeneous K-fibroblast growth factor. In accordance with the methods of the invention, homogeneous K-fibroblast growth factor may be administered to the mammal alone or in combination with other growth factors.
    Type: Grant
    Filed: June 12, 1992
    Date of Patent: July 4, 1995
    Assignee: Genetics Institute, Inc.
    Inventors: David T. Rogers, Neil M. Wolfman, Jasbir S. Seehra
  • Patent number: 5126323
    Abstract: Homogeneous K-FGF and a process for its production are provided. Also provided are pharmaceutical compositions for use in treating soft tissue injuries and musculo-skeletal disorders in mammals and methods of treatment. The purification of the bacterially produced K-FGF comprises reduction of a salt solution containing K-FGF to effect the precipitation of the product.
    Type: Grant
    Filed: November 16, 1989
    Date of Patent: June 30, 1992
    Assignee: Genetics Institute, Inc.
    Inventors: David T. Rogers, Neil M. Wolfman, Jasbir S. Seehra
  • Patent number: 4677195
    Abstract: A method for purifying erythropoietin is described. The method comprises treating partially purifying erythropoietin by reverse phase high performance liquid chromatography to obtain homogeneous erythropoietin having a molecular weight of about 34,000 daltons on SDS PAGE and moving a single peak on reverse phase HPLC. The homogeneous erythropoietin protein preferably has a specific activity of at least 120,000 IU, more preferably at least 160,000 IU per absorbance unit at 280 nm.
    Type: Grant
    Filed: January 11, 1985
    Date of Patent: June 30, 1987
    Assignee: Genetics Institute, Inc.
    Inventors: Rodney M. Hewick, Jasbir S. Seehra